Close Menu

regulatory approval

A new report from the Personalized Medicine Coalition highlights new personalized medicines approvals by the US Food and Drug Administration.

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.

Myriad Genetics' BRACAnalysis CDx can identify which metastatic patients have BRCA mutations and would likely benefit from treatment with AstraZeneca's Lynparza.

The Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.

Pricing for FoundationOne CDx, which received FDA approval and a proposed CMS national coverage determination yesterday, will be determined under PAMA.

The FDA approved FoundationOne CDx and the Centers for Medicare and Medicaid Services concurrently issued a proposed national coverage decision for the test.

The test is designed to detect 14 of the most prevalent mutations in the gene responsible for the disease.

Pages

According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.

An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.

US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.

In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.